Cns Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company has engaged in business development transactions, including an exclusive European license agreement for a Phase 3 radiopharmaceutical asset with Immedica Pharma AB and a preclinical research collaboration with Astellas Pharma, Inc. It focuses on developing a pipeline of neurology and oncology assets, emphasizing novel and differentiated compounds with strong biological rationale. The company also develops clinical and regulatory strategies to support efficient development. Strategic collaborations include partnerships with Memorial Sloan Kettering Cancer Center and Yale University. Market segments served encompass neurology, oncology, central nervous system (CNS), endocrinology, immunology, rare diseases, and gene therapy. Customers and partners mentioned in filings include Astellas Pharma, Inc., Biogen, Caliber I.D., Forge Financial Group, Homology Medicines, Immedica Pharma AB, IO Biotech, Jesup & Lamont, Lucid Technologies, Memorial Sloan Kettering Cancer Center, Protea Biosciences Group, Inc., Shire, Takeda, and Yale University.
Cns Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company has engaged in business development transactions, including an exclusive European license agreement for a Phase 3 radiopharmaceutical asset with Immedica Pharma AB and a preclinical research collaboration with Astellas Pharma, Inc. It focuses on developing a pipeline of neurology and oncology assets, emphasizing novel and differentiated compounds with strong biological rationale. The company also develops clinical and regulatory strategies to support efficient development. Strategic collaborations include partnerships with Memorial Sloan Kettering Cancer Center and Yale University. Market segments served encompass neurology, oncology, central nervous system (CNS), endocrinology, immunology, rare diseases, and gene therapy. Customers and partners mentioned in filings include Astellas Pharma, Inc., Biogen, Caliber I.D., Forge Financial Group, Homology Medicines, Immedica Pharma AB, IO Biotech, Jesup & Lamont, Lucid Technologies, Memorial Sloan Kettering Cancer Center, Protea Biosciences Group, Inc., Shire, Takeda, and Yale University.
Sources:
Cns Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cns Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cns Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
